, 37:266 | Cite as

Criteria for Successful Hepatitis B Vaccination in Adults: Results of a Case Study

  • F. Hofmann
  • N. KraljEmail author
Brief Report



Active immunization is the most important measure for controlling hepatitis B (HB) virus infection. The outcome of HB vaccination has been investigated in only a very small number of cohort studies, some of which found a number of cases of HBV infection.

Material and Methods:

Using a design different from that of earlier studies, we have investigated the occurrence of HBV infection and clinical HB disease in individuals who had a complete HB vaccination series. Reported cases of HB/HBV infections among 1235 German health care workers (HCW) were analyzed with special regard to the question of whether or not HB vaccination had taken place in the past.


23 persons had undergone a complete vaccination series with complete documentation: 18 were non-responders (post-vaccination anti-HBs < 10 IU/l), one was a low-responder (anti-HBs < 100 IU/l), and four were responders (100 IU/l).While all responders seroconvertedwithout clinical sign of hepatitis, ten non-/low-responders contracted chronic HB/HBV infection and seven contracted self-limiting HB.


Vaccination should be only regarded as “successful”, if the post-vaccination anti-HBs concentration is at least 100 IU/l.


Additional Booster Dose Successful Hepatitis German Health Care Worker Yeast Recombinant Vaccine Complete Vaccination Series 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Goudeau A, Coursaget P, Barin F, Dubois F, Chiron JP, Denis F, Diop-Mar J: Prevention of hepatitis B by active and passiveactive immunization. In: Szmuness W, Alter HJ, Maynard JE (eds): Viral Hepatitis, 1981 International Symposium. The Franklin Institute Press, Philadelphia 1982, pp 509–525.Google Scholar
  2. 2.
    Robert Koch-Institut, Berlin: Empfehlungen der Ständigen Impfkommission (STIKO) am Robert Koch-Institut — Stand: July 2005 (Recommendations of the Permanent Commission for Vaccinations on Robert Koch-Institute, in German). Epidemiol Bull 2005; 30: 257–274.Google Scholar
  3. 3.
    Couroucé AM, Laplanche A, Benhamou E, Jungers P: Long-term efficacy of hepatitis B vaccination in healthy adults. In: Zuckerman AJ (eds): Viral Hepatitis and Liver Disease. Alan R Liss Inc, New York 1988, pp 1002–1005.Google Scholar
  4. 4.
    Gibas A, Watkins E, Hinkle C, Dienstag JL: Long-term persistence of protective antibody after hepatitis B vaccination of healthy adults. In: Zuckerman AJ (eds): Viral Hepatitis and Liver Disease. Alan R Liss Inc, New York 1988, pp 998–1001.Google Scholar
  5. 5.
    Bell DM, Shapiro CN, Ciesielski CA, Chamberland ME: Preventing bloodborne pathogen transmission from health-care workers to patients — The CDC perspective. Surg Clin North Am 1995; 75: 1189–1203.PubMedGoogle Scholar
  6. 6.
    Hadler SC, Francis DP, Maynard JE, Thompson SE, Judson FN, Echenberg DF, Ostrow DG, O’Malley PM, Penley KA, Altman NL: Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men. N Engl J Med 1986; 315: 209–214.PubMedGoogle Scholar
  7. 7.
    Hadler SC, Coleman PJ, O’Malley P, Judson FN, Altman N: Evaluation of long-term protection by hepatitis B vaccine for seven to nine years in homosexual men. In: Hollinger FB, Lemon SM, Margolis H (eds): Viral hepatitis, liver disease. Williams and Wilkins, Baltimore 1991, pp 766–768.Google Scholar
  8. 8.
    Stevens CE, Taylor PE, Tong MJ, Toy PT, Vyas GN: Hepatitis-Bvaccine: An overview. In: Yvas GN, Dienstag JL, Hoofnagle JH (eds): Viral hepatitis and liver disease. Grune and Stratton, Orlando 1984, pp 275–291.Google Scholar
  9. 9.
    Wainwright RB, McMahon BL, Bulkow LR, Parkinson AJ, Harpster AP, Hadler SC: Duration of immunogenicity and efficacy of hepatitis B vaccine in a Yupik Eskimo population — preliminary results of an 8-year study. In: Hollinger FB, Lemon SM, Margolis H (eds): Viral hepatitis and liver disease. Williams and Wilkins, Philadelphia 1991, pp 762–766.Google Scholar
  10. 10.
    Schenkel K, Radun D, Bocter N, Hamouda O: Viral hepatitis in Germany: poor vaccination coverage and little knowledge about transmission in target groups. BMC Public Health 2008; 8: 132–143.PubMedCrossRefGoogle Scholar
  11. 11.
    Hofmann F, Hambraeus L, Hagberg M, Böttiger M: Berufsbedingte Infektionskrankheiten beim Personal des schwedischen und des bundesdeutschen Gesundheitsdienstes (occupationally acquired infectious diseases in Swedish and German Health Care Workers — in German). In: Hofmann F, Stössel U (eds): Arbeitsmedizin im Gesundheitsdienst 5 (occupational health in health care workers 5). Gentner Verlag, Stuttgart 1991, pp 127–131.Google Scholar
  12. 12.
    Tanner J, Parkinson H: Double gloving to reduce surgical crossinfection (Cochrane Review) In: The Cochrane Library, Issue 3, Oxford, Update Software 2003.Google Scholar
  13. 13.
    Dale J, Pruett S, Maker M: Accidental needlesticks in the phlebotomy service of the Department of Laboratory Medicine and Pathology at Mayo Clinic Rochester. Mayo Clin Proc 1998; 73: 611–615.PubMedCrossRefGoogle Scholar

Copyright information

© Springer 2008

Authors and Affiliations

  1. 1.Chair for Physiology Occupational Medicine and Prevention of Infectious diseasesUniversity of WuppertalWuppertalGermany

Personalised recommendations